Making the COVID-19 Oral Treatment: How 2,000+ Pfizer Team Members Made It Happen
As the potential threat of COVID-19 became clear by early 2020, teams across Pfizer sprang into action. Together, they worked to better understand the novel virus.
fully human anti-PD-L1 IgG1 monoclonal antibody, in patients fully human anti-PD-L1 IgG1 monoclonal antibody. By …
the Indiegogo platform at http://igg.me/getold . Submissions must be …
as avelumab, a fully human anti-PD-L1 IgG1 monoclonal antibody (also known …
in phase 2, is a fully human igG2 monoclonal antibody which has …
as measured by RBD-binding IgG concentrations and SARS-CoV-2 …
CP-751,871 CP-751,871, a fully human IgG2 monoclonal antibody, is a highly …
immunoglobulin G isotype, subclass 1 (IgG1) that targets the Kunitz 2 domain …
fully human anti-PD-L1 IgG1 monoclonal antibody, in an fully human anti-PD-L1 IgG1 monoclonal antibody. By …
fully human anti-PD-L1 IgG1 monoclonal antibody being …
Hypogammaglobulinemia (IgA, IgG, or IgM below the lower limit of levels at baseline had low IgA, IgG, and IgM levels, respectively, …
Behind the Science Features
Press Releases
06.01.2022
06.01.2022
05.31.2022
05.26.2022
05.25.2022
05.25.2022
05.24.2022
05.23.2022
05.20.2022
Press Releases, Partnering News
05.17.2022
05.13.2022
05.13.2022
Media Resources
This information is intended for media professionals. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Clinical Trials
Our Careers